Zhitong Finance App News, Laikai Pharmaceutical-B (02105.HK) announced that the Group has completed the Phase III clinical trial of LAE002 (afuresertib) combined with fluvirizil for the treatment of patients with HR+/HER2-locally advanced or metastatic breast cancer (“LA/MBC”) with PIK3CA/AKT1/PTEN gene changes.

Zhitong Finance App News, Laikai Pharmaceutical-B (02105.HK) announced that the Group has completed the Phase III clinical trial of LAE002 (afuresertib) combined with fluvirizil for the treatment of patients with HR+/HER2-locally advanced or metastatic breast cancer (“LA/MBC”) with PIK3CA/AKT1/PTEN gene changes.